Meeting
2024 ASCO Genitourinary Cancers Symposium
ERBB3 expression in racially diverse patients with castration-sensitive prostate cancer and its association with a unique AR activity signature.
Authors
Jordan Vellky
University of Illinois Chicago, Chicago, IL
Jordan Vellky , Donald Vander Griend , Natalie Marie Reizine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Cancer Disparities
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 23)
DOI
10.1200/JCO.2024.42.4_suppl.23
Abstract #
23
Poster Bd #
A2
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).
First Author: Eddy Shih-Hsin Yang
Poster
2020 Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.
First Author: Di Maria Jiang
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.
First Author: Amy K Taylor
Poster
2023 ASCO Genitourinary Cancers Symposium
Therapeutic potential of plant-derived nanovesicles for neuroendocrine prostate cancer.
First Author: Sharanjot Saini